Cirtuvivint for selected advanced soft‑tissue sarcomas

Multicenter, Open-Label Phase II Trial of Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

This trial will test whether the oral drug cirtuvivint can help control tumors in people aged 16–70 with certain advanced soft‑tissue sarcomas after prior treatment.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Ages: 16 Years to 70 Years
• Sex: All
• Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas (Academic / other)
• Locations: 1 site (Madrid, Madrid)
• Trial ID: NCT07032285 on ClinicalTrials.gov

What this trial studies

This Phase 2 study will give oral cirtuvivint to approximately 25 patients in Spain who have advanced, unresectable soft‑tissue sarcomas of specified subtypes as a second‑line treatment. Cirtuvivint is an investigational tablet that inhibits CLK1‑4 and DYRK1‑4 kinases involved in cell cycle regulation. The primary objective is to measure clinical efficacy in these selected histologies while monitoring safety and tolerability. The product is not approved in Europe, and one site will include two desmoid tumor patients as an exploratory proof of concept.

Who should consider this trial

Good fit: Adults aged 16–70 with advanced unresectable soft‑tissue sarcoma of the listed subtypes (solitary fibrous tumor, synovial sarcoma, clear cell sarcoma, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, myxoid liposarcoma) who are not candidates for curative surgery and require second‑line therapy are the intended participants.

Not a fit: Patients with other sarcoma subtypes, those who cannot take oral kinase inhibitors, or those with medical contraindications to trial participation are unlikely to benefit from this study.

Why it matters

Potential benefit: If successful, cirtuvivint could offer a new oral treatment option to extend disease control for patients with these rare sarcoma subtypes.

How similar studies have performed: CLK/DYRK kinase inhibition is a relatively novel approach in sarcoma; preclinical data and early‑phase work suggest potential activity but clinical benefit in these specific subtypes has not been established.

Eligibility criteria

Inclusion criteria:

1. Patients must provide written informed consent prior to performance of any study-specific procedures and must be willing to comply with treatment and follow up. Informed consent must be obtained prior to the start of the screening process. Procedures conducted as part of the patient's routine clinical management (e.g., imaging tests), obtained prior to signature of informed consent may be used for screening or baseline purposes as long as these procedures are conducted as specified in the protocol.
2. Age: 16-70 years.
3. Patients with a diagnosis of advanced unresectable soft-tissue sarcoma and not candidates for surgical rescue including only the following subtypes: solitary fibrous tumor (SFT), synovial sarcoma, clear cell sarcoma, extraskeletal myxoid chondrosarcoma (EMC), alveolar soft part sarcoma and myxoid liposarcoma. Additionally, the Hospital Universitario Fundación Jiménez Díaz will include 2 desmoid tumor patients as proof of concept outside the total n.
4. Metastatic/locally advanced with recent progression (\<6 months).
5. Patients should have received at least anthracyclines previously unless not indicated (SFT).
6. Measurable disease according to RECIST 1.1 criteria.
7. Patients must be willing to provide consent for the provision of mandatory biological samples for central pathology review (tumor sample from the three months prior to the start of treatment if the patient has not received any systemic therapy) and translational study (tumor blocks and blood).
8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
9. Adequate hepatic, renal, cardiac, and hematologic function.
10. Laboratory tests as follows:

    * Absolute neutrophil count ≥1,500/mm³
    * Platelet count ≥100,000/mm³
    * Bilirubin ≤1.5 mg/dL
    * AST and ALT ≤2.5 times upper limit of normal
    * Creatinine ≤1.5 mg/dL
11. Left ventricular ejection fraction ≥50% by echocardiogram or MUGA scan.
12. Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to enrollment and agree to use birth control measures during study treatment and for 3 months after its completion. Patients must not be pregnant or nursing at study entry. Women/men of reproductive potential must have agreed to use a highly effective contraceptive method.
13. Subjects must be willing to avoid extensive sun exposure, phototherapy, and use of a tanning salon during trial participation.

Exclusion criteria:

Patients meeting any of the following exclusion criteria are not eligible to be enrolled in this study:

1. Previous treatment with CLK inhibitors.
2. Patients who have received any other anti-cancer therapy or investigational product in the last 28 days prior to enrollment.
3. Four or more systemic therapy lines for advanced disease.
4. Sarcoma subtypes other than the specified in the inclusion criteria.
5. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer, adequately treated cervical carcinoma in situ, superficial bladder carcinoma) during the 3 years prior to enrollment. Cancer treated with curative intent for \>5 years previously and without evidence of recurrence will be allowed.
6. Any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
7. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.
8. Pregnant or breastfeeding females.
9. Body surface area (BSA) \<1.4 m2 at baseline, calculated by the Du Bois (33) or Mosteller (34) method.
10. Life expectancy of less than 3 months.
11. Major surgery within 28 days prior to C1D1.
12. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or dysfunction that could interfere with absorption of study treatment.
13. Inability or unwillingness to take supportive medications such as anti-nausea and anti anorexia agents as recommended by the NCCN CPGO for antiemesis and anorexia/cachexia (palliative care).
14. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.
15. Subjects with a corrected QT interval (QTc) using Fridericia's formula (QTcF) \> CTCAE v5.0 Grade 1 (\>480 msec) based on the mean of triplicate evaluation at screening. In subjects with ventricular paced rhythm, a 50 msec subtraction should be applied to the QTc to calculate the QTcF, potential exceptions for subjects with pacemakers should be discussed with the Medical Monitor.
16. Subjects with clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), ventricular fibrillation (VF), second or third degree heart block.
17. Subjects with myocardial infarction (MI) within 1 year, Class II-IV congestive heart failure (CHF) per New York Heart Association (NYHA) classification, or clinically significant coronary artery disease (CAD).
18. Subjects currently using or anticipating the need for food or drugs known to strongly inhibit or induce CYP3A4, such as ketoconazole, itraconazole, erythromycin, or rifampin, within 10 days prior to first dose of study medication.
19. Subjects with retinal abnormalities, specifically diabetic retinopathy, macular degeneration, other forms of retinal degenerative disease, or other retinal findings that may place the subject at risk (the latter should be discussed with the Medical Monitor).
20. Subjects with known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
21. Patient is unwilling to participate in the translational study (not providing mandatory written consent for tumor and blood samples).

Where this trial is running

Madrid, Madrid

• Medical Oncology Department, HU Fundación Jimenez Diaz — Madrid, Madrid, Spain (Recruiting)

Study contacts

• Study coordinator: Nadia Hindi, MD

Conditions Soft Tissue Sarcoma